Title Antiviral Activity of 3,4'-Dihydroxyflavone on Influenza A Virus
Author Mohammed Kawser Hossain1, Hye Yeon Choi1, Jae-Seon Hwang2, Ahmed Abdal Dayem1, Jung-Hyun Kim1, Young Bong Kim3, Haryoung Poo2, and Ssang-Goo Cho1*
Address 1Department of Animal Biotechnology, Animal Resources Research Center, and Incurable Disease Animal model and Stem cell Institute (IDASI), Konkuk University, Seoul 143-701, Republic of Korea, 2Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-333, Republic of Korea, 3Department of Bioindustrial Technologies, Konkuk University, Seoul 143-701, Republic of Korea
Bibliography Journal of Microbiology, 52(6),521-526, 2014,
DOI 10.1007/s12275-014-4212-z
Key Words flavonoid, 3-hydroxyl group flavonoids, 3,4'-dihydroxyflavone, influenza virus
Abstract Influenza virus infection causes thousands of deaths and millions of hospitalizations worldwide every year and the emergence of resistance to anti-influenza drugs has prompted scientists to seek new natural antiviral materials. In this study, we screened 13 different flavonoids from various flavonoid groups to identify the most potent antiviral flavonoid against human influenza A/PR/8/34 (H1N1). The 3-hydroxyl group flavonoids, including 3,2'-dihydroxyflavone (3,2'-DHF) and 3,4'-dihydroxyflavone (3,4'-DHF), showed potent anti-influenza activity. They inhibited viral neuraminidase activity and viral adsorption onto cells. To confirm the anti-influenza activity of these flavonoids, we used an in vivo mouse model. In mice infected with human influenza, oral administration of 3,4'-DHF significantly decreased virus titers and pathological changes in the lung and reduced body weight loss and death. Our data suggest that 3-hydroxyl group flavonoids, particularly 3,4'-DHF, have potent antiviral activity against human influenza A/PR/8/34 (H1N1) in vitro and in vivo. Further clinical studies are needed to investigate the therapeutic and prophylactic potential of the 3-hydroxyl group flavonoids in treating influenza pandemics.